Status and phase
Conditions
Treatments
About
Primary Objective:
To determine whether daily administration of dronedarone started 5-7 days before cardioversion is superior to dronedarone started only after cardioversion with respect to the absence of symptomatic, ECG confirmed, atrial fibrillation (AF) recurrence over 6 months in adult patients with persistent AF, for whom cardioversion is clinically indicated and planned to reduce symptoms and antiarrhythmic treatment is clinically indicated to reduce the risk of cardiovascular hospitalization due to AF.
Secondary Objectives:
Main Secondary :
Other secondary:
Full description
The study period of approximatively 6 months consisted in:
Double-blind treatment period (placebo or dronedarone) for 5-7 days prior to cardioversion; Electrical cardioversion; Open-label treatment period with dronedarone for 6 months after cardioversion.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Concomitant drugs:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
292 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal